Glioblastoma (GBM) or astrocytoma grade IV according to the World Health Organization (WHO) classification is the most aggressive and common of all primary brain tumors, accounting for approximately 40% of all primary and 78% of all malignant central nervous system tumors.1,2 Mutations (TP53, p16INK4a, p14ARF, and PTEN), amplifications (EGFR and CDK4/6) and loss of heterozygosity (LOH) of several chromosomes (1p, 6q, 9p, 10p, 10q, 13q, 14q, 15q, 17p, 18q, 19q, 22q, and Y) are among the major genetic alterations found in GBMs.3–5. This evidence concerns the gene CDKN2A and glioblastoma.